BioCentury | Apr 13, 2009
Clinical News

TerbiMed: Phase II data

...recurrence. Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) markets Lamisil to treat onychomycosis and tinea capitis. MedPharm Ltd....
BioCentury | Mar 9, 2009
Company News

MedPharm, Moberg Derma, Zelmic AB deal

...Moberg received an exclusive, worldwide license to use MedPharm's MedSpray sprayable drug delivery technology to develop...
...development, for which it will receive consulting and development fees. Further terms were not disclosed. MedPharm Ltd....
BioCentury | Nov 19, 2007
Clinical News

MedSpray: Phase II start

...next year, MedPharm will begin a Phase II trial of MedSpray using an undisclosed antifungal. MedPharm Ltd....
BioCentury | Apr 17, 2006
Company News

MedPharm board of directors update

MedPharm Ltd. , London, U.K. Business: Drug delivery Appointed: Geoffrey Vernon, chairman of Ziggus Holdings, as chairman WIR Staff...
BioCentury | Feb 14, 2005
Company News

MedPharm, OptiNose A/S deal

...OptiNose's nasal delivery technology with MedPharm's capabilities in formulating poorly soluble drugs and powder engineering. MedPharm Ltd....
BioCentury | Jun 4, 2001
Company News

KS Biomedix, MedPharm deal

...KSB will develop with MedPharm a solid suppository formulation of its KSB304 antibody to treat ulcerative...
...be associated with inflammatory responses in ulcerative colitis. KS Biomedix Holdings plc (LSE:KSB), London, U.K MedPharm Ltd....
BioCentury | May 29, 2001
Company News

KS Biomedix, MedPharm in antibody deal

...KS Biomedix (LSE:KSB) will develop with MedPharm (London, U.K.) a solid suppository dosage form of its...
Items per page:
1 - 7 of 7
BioCentury | Apr 13, 2009
Clinical News

TerbiMed: Phase II data

...recurrence. Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) markets Lamisil to treat onychomycosis and tinea capitis. MedPharm Ltd....
BioCentury | Mar 9, 2009
Company News

MedPharm, Moberg Derma, Zelmic AB deal

...Moberg received an exclusive, worldwide license to use MedPharm's MedSpray sprayable drug delivery technology to develop...
...development, for which it will receive consulting and development fees. Further terms were not disclosed. MedPharm Ltd....
BioCentury | Nov 19, 2007
Clinical News

MedSpray: Phase II start

...next year, MedPharm will begin a Phase II trial of MedSpray using an undisclosed antifungal. MedPharm Ltd....
BioCentury | Apr 17, 2006
Company News

MedPharm board of directors update

MedPharm Ltd. , London, U.K. Business: Drug delivery Appointed: Geoffrey Vernon, chairman of Ziggus Holdings, as chairman WIR Staff...
BioCentury | Feb 14, 2005
Company News

MedPharm, OptiNose A/S deal

...OptiNose's nasal delivery technology with MedPharm's capabilities in formulating poorly soluble drugs and powder engineering. MedPharm Ltd....
BioCentury | Jun 4, 2001
Company News

KS Biomedix, MedPharm deal

...KSB will develop with MedPharm a solid suppository formulation of its KSB304 antibody to treat ulcerative...
...be associated with inflammatory responses in ulcerative colitis. KS Biomedix Holdings plc (LSE:KSB), London, U.K MedPharm Ltd....
BioCentury | May 29, 2001
Company News

KS Biomedix, MedPharm in antibody deal

...KS Biomedix (LSE:KSB) will develop with MedPharm (London, U.K.) a solid suppository dosage form of its...
Items per page:
1 - 7 of 7